BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Larotrectinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Larotrectinib\, from ClinicalTrials.gov e
 stimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04655404-2586@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Larotrectinib: Phase 1 readout est. (NCT04655404)
DESCRIPTION:Larotrectinib\, phase 1.\nStudy: A Pilot Study of Larotrectinib
  for Newly-Diagnosed High-Grade Glioma With NTRK Fusion\nEstimated primary
  completion: 1 December 2026. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/larotrectinib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT04655404
URL:https://assetmemo.bio/drug/larotrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07843550-2586@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20270713
DTEND;VALUE=DATE:20270714
SUMMARY:Larotrectinib: Phase 1/2 readout est. (NCT07843550)
DESCRIPTION:Larotrectinib\, phase 1/2\, Solid Tumors.\nStudy: A Phase 1/2 T
 rial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Prev
 iously Treated With Immune Checkpoint Inhibitor Monotherapy\nEstimated pri
 mary completion: 13 July 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/larotrectinib#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07843550
URL:https://assetmemo.bio/drug/larotrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06563999-2586@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Larotrectinib: Phase 2 readout est. (NCT06563999)
DESCRIPTION:Larotrectinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: N
 eoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC H
 arboring Rare Mutations.\nEstimated primary completion: 1 November 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/larotrectinib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06563999
URL:https://assetmemo.bio/drug/larotrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04879121-2586@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20271111
DTEND;VALUE=DATE:20271112
SUMMARY:Larotrectinib: Phase 2 readout est. (NCT04879121)
DESCRIPTION:Larotrectinib\, phase 2\, Solid Tumors.\nStudy: Larotrectinib f
 or the Treatment of NTRK Amplification Positive\, Locally Advanced or Meta
 static Solid Tumors\nEstimated primary completion: 11 November 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/larotrectinib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT04879121
URL:https://assetmemo.bio/drug/larotrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02465060-2586@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Larotrectinib: Phase 2 readout est. (NCT02465060)
DESCRIPTION:Larotrectinib\, phase 2\, Solid Tumors.\nStudy: Targeted Therap
 y Directed by Genetic Testing in Treating Patients With Advanced Refractor
 y Solid Tumors\, Lymphomas\, or Multiple Myeloma (The MATCH Screening Tria
 l)\nEstimated primary completion: 31 December 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/larotrectinib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT02465060
URL:https://assetmemo.bio/drug/larotrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07010393-2586@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Larotrectinib: Phase 4 readout est. (NCT07010393)
DESCRIPTION:Larotrectinib\, phase 4.\nStudy: Genotype-Driven Neoadjuvant Th
 erapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study\nEsti
 mated primary completion: 31 December 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/larotrectinib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07010393
URL:https://assetmemo.bio/drug/larotrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07908147-2586@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Larotrectinib: Phase 1 readout est. (NCT07908147)
DESCRIPTION:Larotrectinib\, phase 1.\nStudy: Biomarker-guided RAdiation-def
 erring Treatment in Younger GBM Patients - Pilot Study\nEstimated primary 
 completion: March 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/larotrectinib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07908147
URL:https://assetmemo.bio/drug/larotrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05783323-2586@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Larotrectinib: Phase 2 readout est. (NCT05783323)
DESCRIPTION:Larotrectinib\, phase 2.\nStudy: Larotrectinib to Enhance RAI A
 vidity in Differentiated Thyroid Cancer\nEstimated primary completion: 1 O
 ctober 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/larotrec
 tinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05783323
URL:https://assetmemo.bio/drug/larotrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05725200-2586@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20381231
DTEND;VALUE=DATE:20390101
SUMMARY:Larotrectinib: Phase 2 readout est. (NCT05725200)
DESCRIPTION:Larotrectinib\, phase 2.\nStudy: Study to Investigate Outcome o
 f Individualized Treatment in Patients With Metastatic Colorectal Cancer\n
 Estimated primary completion: 31 December 2038. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/larotrectinib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05725200
URL:https://assetmemo.bio/drug/larotrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
